Autolus director granted options and RSUs
Autolus Therapeutics plc director Robert Azelby received new equity awards in the form of options and restricted share units tied to the company’s American Depositary Shares.
Rhea-AI Filing Summary
Autolus Therapeutics plc director Robert Azelby received new equity awards in the form of options and restricted share units tied to the company’s American Depositary Shares. On June 29, 2026, he was granted options over 47,500 ADSs at an exercise price of $1.61 per share, vesting in twelve equal monthly installments starting July 29, 2026. He also received 31,667 restricted share units covering 31,667 ADSs, which vest in a single installment on June 29, 2027. Each RSU represents a contingent right to receive one ADS, and each ADS is convertible into one ordinary share.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Share Units | 31,667 | $0.00 | $0.00 |
| Grant/Award | Share Option (Right to Buy) | 47,500 | $0.00 | $0.00 |
Footnotes (3)
- F1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.
- F2. The RSUs vest in one installment on June 29, 2027.
- F3. Share options vest in twelve equal monthly installments commencing on July 29, 2026.
Key Figures
Key Terms
restricted stock unit (RSU) financial
vest in twelve equal monthly installments financial
FAQ
What insider transactions did Autolus Therapeutics (AUTL) report for Robert Azelby?
How many options did Robert Azelby receive from Autolus Therapeutics (AUTL) and at what price?
What are the vesting terms of Robert Azelby’s Autolus Therapeutics (AUTL) stock options?
When do Robert Azelby’s Autolus Therapeutics (AUTL) RSUs vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.